An epithelial-mesenchymal transition (EMT) is a biologic process that allows a polarized epithelial cell, which normally interacts with basement membrane via its basal surface, to undergo multiple biochemical changes that enable it to assume a mesenchymal cell phenotype, which includes enhanced migratory capacity, invasiveness, elevated resistance to apoptosis, and greatly increased production of ECM components”. EMT was classified into three types, based on its activity in the human body at varied events during: 1) Embryogenesis, 2) Physiological Wound healing and Fibrosis, 3) Cancer Progression. There are numerous molecular signaling pathways involved in EMT during cancer progression & metastasis. Numerous therapeutic targets have been developed against these altered EMT signaling pathways as a treatment modality.

[1] Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009 Jun;119(6):1420-8. doi: 10.1172/JCI39104. Erratum in: J Clin Invest. 2010 May 3;120(5):1786. PMID: 19487818; PMCID: PMC2689101.

[2] Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, García de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RYJ, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagué J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G; EMT International Association (TEMTIA). Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020 Jun;21(6):341- 352. “DOI: 10.1038/s41580-020-0237-9. Epub 2020 Apr 16. Erratum in: Nat Rev Mol Cell Biol. 2021 Dec;22(12):834. PMID: 32300252; PMCID: PMC7250738”.

[3] Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009 Nov 25;139(5):871-90. doi: 10.1016/j.cell.2009.11.007. PMID: 19945376.

[4] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96. doi: 10.1038/nrm3758. PMID: 24556840; PMCID: PMC4240281.

[5] Ribatti D, Tamma R, Annese T. Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol. 2020 Jun;13(6):100773. doi: 10.1016/j.tranon.2020.100773. Epub 2020 Apr 22. PMID: 32334405; PMCID: PMC7182759.

[6] Dongre A, Weinberg RA. New insights into the mechanisms of epithelialmesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84. doi: 10.1038/s41580-018-0080-4. PMID: 30459476.

[7] Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010 Feb;101(2):293-9. doi: 10.1111/j.1349- 7006.2009.01419.x. Epub 2009 Oct 28. PMID: 19961486

[8] Ramos FS, Wons L, Cavalli IJ, Ribeiro EM. Epithelial-mesenchymal transition in cancer: An overview. Integr Cancer Sci Therap. (2017) 4: DOI: 10.15761/ICST.1000243.

[9] Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules. 2016 Jul 22;21(7):965. doi: 10.3390/molecules21070965. PMID: 27455225; PMCID: PMC6273543.

[10]. Jonckheere S, Adams J, De Groote D, Campbell K, Berx G, Goossens S. EpithelialMesenchymal Transition (EMT) as a Therapeutic Target. Cells Tissues Organs. 2021 Jan 5:1-26. doi: 10.1159/000512218. Epub ahead of print. PMID: 33401271

[11]Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018 Jan 24;13:395-412. doi: 10.1146/annurev-pathol-020117-043854. PMID: 29414248. .

[12]Lai X, Li Q, Wu F, Lin J, Chen J, Zheng H and Guo L (2020) EpithelialMesenchymal Transition and Metabolic Switching in Cancer: Lessons From Somatic Cell Reprogramming. Front. Cell Dev. Biol. 8:760. doi: 10.3389/fcell.2020.00760

[13]Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005 Nov 14;24(50):7443-54. doi: 10.1038/sj.onc.1209091. PMID: 16288291.

[14] RIwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010 Feb;101(2):293-9. doi: 10.1111/j.1349- 7006.2009.01419.x. Epub 2009 Oct 28. PMID: 19961486